Brokerages Set Avalyn Pharma Inc. (NASDAQ:AVLN) Price Target at $60.00

Posted by Brenda Bartman on Sep 13th, 2026

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $60.00.

AVLN has been the subject of a number of analyst reports. Evercore initiated coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target for the company. Wall Street Zen raised Avalyn Pharma from a “sell” rating to a “hold” rating in a research note on Saturday. Jefferies Financial Group assumed coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Finally, Morgan Stanley upped their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th.

Get Our Latest Research Report on Avalyn Pharma

Institutional Investors Weigh In On Avalyn Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth about $236,000. Bank of New York Mellon Corp bought a new stake in Avalyn Pharma during the 2nd quarter valued at approximately $1,321,000. Braidwell LP acquired a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $26,382,000. Finally, Montanova Capital LLC bought a new position in Avalyn Pharma in the 2nd quarter worth approximately $82,402,000.

Avalyn Pharma Stock Down 3.2%

Shares of AVLN opened at $33.57 on Friday. The firm has a market cap of $1.49 billion and a price-to-earnings ratio of -1.47. The business’s fifty day simple moving average is $32.79. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a 12 month low of $24.15 and a 12 month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05. As a group, research analysts predict that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.